Figures & data
Figure 1 Scheme graph (A) and TEM image (B) of doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers (DOX/ELE Hyd NLCs).
![Figure 1 Scheme graph (A) and TEM image (B) of doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers (DOX/ELE Hyd NLCs).](/cms/asset/d50fd4d0-4cec-454a-ab83-302dcd554d1e/dddt_a_12182075_f0001_c.jpg)
Table 1 EE and DL of NLCs (mean ± SD, n=3)
Figure 2 Particle sizes (A), polydispersity indices (B), and zeta potentials (C) of NLCs. Data are presented as mean ± SD, n=10.
![Figure 2 Particle sizes (A), polydispersity indices (B), and zeta potentials (C) of NLCs. Data are presented as mean ± SD, n=10.](/cms/asset/07b61d4d-9c81-4201-9892-e17d195f599a/dddt_a_12182075_f0002_c.jpg)
Figure 3 Plasma stability of NLCs evaluated simulated in 10% FBS. NLCs showed no significant size (A) and PDI (B) changes during the 72-hr test. Data are presented as means ± SD, n=10.
![Figure 3 Plasma stability of NLCs evaluated simulated in 10% FBS. NLCs showed no significant size (A) and PDI (B) changes during the 72-hr test. Data are presented as means ± SD, n=10.](/cms/asset/319176ee-aa52-4b97-ac13-40aced0ef999/dddt_a_12182075_f0003_c.jpg)
Figure 4 In vitro release behavior of pH-sensitive DOX/ELE Hyd NLCs (A) and DOX/ELE NLCs (B) at pH 5.5 and 7.4. Data are presented as means ± SD, n=3.
![Figure 4 In vitro release behavior of pH-sensitive DOX/ELE Hyd NLCs (A) and DOX/ELE NLCs (B) at pH 5.5 and 7.4. Data are presented as means ± SD, n=3.](/cms/asset/335762fa-34ed-44cc-a14f-751b05fbe526/dddt_a_12182075_f0004_c.jpg)
Figure 5 Cellular uptake efficiency of NLCs was illustrated by coumarin-6-loaded NLCs in A549/ADR cells: flow cytometery results (A) and microscopy images. (B) Data are presented as means ± SD, n=6.
![Figure 5 Cellular uptake efficiency of NLCs was illustrated by coumarin-6-loaded NLCs in A549/ADR cells: flow cytometery results (A) and microscopy images. (B) Data are presented as means ± SD, n=6.](/cms/asset/dc2c7fb1-ffb7-480e-8462-f84f984ba06a/dddt_a_12182075_f0005_c.jpg)
Figure 6 In vitro cytotoxicity of NLCs was evaluated on both A549 (A), A549/ADR cells (B), and MRC-5 cells (C). CI50 was measured to validate the synergistic effect (D). Data is presented as mean ± SD, n=6.
![Figure 6 In vitro cytotoxicity of NLCs was evaluated on both A549 (A), A549/ADR cells (B), and MRC-5 cells (C). CI50 was measured to validate the synergistic effect (D). Data is presented as mean ± SD, n=6.](/cms/asset/7266bc64-c1b3-4749-b5fe-cc9e00ebf686/dddt_a_12182075_f0006_c.jpg)
Figure 7 In vivo tissue distribution of NLCs and drugs injection (INJ) in tumor xenografts: DOX distribution at 1 hr (A) and 24 hr (B); ELE distribution at 1 hr (C) and 24 hr (D). Data is presented as means ± SD, n=8.
![Figure 7 In vivo tissue distribution of NLCs and drugs injection (INJ) in tumor xenografts: DOX distribution at 1 hr (A) and 24 hr (B); ELE distribution at 1 hr (C) and 24 hr (D). Data is presented as means ± SD, n=8.](/cms/asset/0c789321-3880-41bf-8138-071189b24d48/dddt_a_12182075_f0007_c.jpg)
Table 2 Tumor inhibition ratios (mean ± SD, n=3)